Develop and commercialize TXNIP [tix-nip] inhibiting medication as a first-of-its-kind oral therapeutic for Type 1 and Type 2 Diabetes.
Develop and commercialize TXNIP [tix-nip] inhibiting medication as a first-of-its-kind oral therapeutic for Type 1 and Type 2 Diabetes.
Diabetes is a major global and local health problem.
Diabetes currently affects 425 million people worldwide.
>34 million people in the U.S. have diabetes.
88 million adults in the U.S. have pre-diabetes.
There are no oral medications for Type 1 diabetes.
To stay alive, individuals with Type 1 diabetes require multiple daily insulin injections and/or continuous insulin infusion.
None of the current medications address the problem of excessive glucagon levels associated with diabetes.
There is no approved treatment available for non-alcoholic fatty liver disease (NAFLD), often associated with diabetes.
No specific drug is available to inhibit TXNIP (thioredoxin-interacting protein), a newly identified therapeutic target.
There are no oral medications for Type 1 diabetes.
To stay alive, individuals with Type 1 diabetes require multiple daily insulin injections and/or continuous insulin infusion.
None of the current medications address the problem of excessive glucagon levels associated with diabetes.
There is no approved treatment available for non-alcoholic fatty liver disease (NAFLD), often associated with diabetes.
No specific drug is available to inhibit TXNIP (thioredoxin-interacting protein), a newly identified therapeutic target.
TIXiMED offers a solution – TIX100.
TIX100 is a novel, non-toxic small molecule that, given orally, protects against models of Type 1 and Type 2 diabetes as well as NAFLD.
TIXiMED is the exclusive license holder for the underlying patent (composition of matter and method of use) surrounding the TIX100 molecule.
How TIX100 Works
The TIX100 Advantage
Strong, peer-reviewed preclinical data (Thielen…Shalev, Cell Metabolism 2020)
TIX100 specifically targets TXNIP (approach that has successfully been translated to humans with T1D – see verapamil trial, Ovalle…Shalev, Nature Medicine 2018)
TIX100 is 100-times more effective in inhibiting TXNIP than verapamil
TIX100 is taken orally. By contrast, subjects with T1D need insulin given by multiple daily subcutaneous injections or an infusion to survive, and no oral medications are available.
TIX100 targets the underlying causes of the disease. It brings the elevated TXNIP levels back down into the normal range, protects beta cell insulin production, and inhibits the excessive secretion of glucagon typically seen in diabetes. (Glucagon counters the effects of insulin, making the blood sugar go even higher.) By doing so, TIX100 is also effective in the face of insulin deficiency.
Unlike current experimental glucagon receptor antagonist drugs, TIX100 lowers serum glucagon levels, reduces blood lipids, and protects against fatty liver, suggesting that it may also be effective in the context of NAFLD or non-alcoholic steatohepatitis (NASH).
Moving Forward
TIXiMED is targeting the third quarter of 2023 to begin Phase I human trials to demonstrate clinical safety.
Moving Forward
TIXiMED is targeting early 2024 to begin Phase I human trials to demonstrate clinical safety.